OBI Pharma is developing novel therapeutic agents
for unmet medical needs.
OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network’s OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL
First clinical trial to evaluate the safety and efficacy of OBI-3424, a DNA alkylating agent targeting AKR1C3 enzyme, in T-Cell Acute Lymphocytic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) TAIPEI, Taiwan, April 26, 2021 — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S.-based SWOG Cancer …
Poster Presentation at AACR 2021 Annual Meeting for OBI-3424, OBI-998, GLOBO H and SSEA-4
Title: Selective and Broad Anti-tumor Activity of AKR1C3-activated Prodrug AST-3424/OBI-3424 Poster Number: 1220 / Abstract number: 1062 Title: Preclinical characterization of a novel SSEA4-targeting antibody drug conjugate, OBI-998 Poster number: 955 / Abstract number: 1238 Title: Inhibitory activity of Globo-H and SSEA-4 on activated T cells Poster number: 3176 / …
OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4
Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 small molecule pro-drug), OBI-998 (SSEA-4 ADC) and the glycosphingolipid cancer antigens, Globo H and SSEA-4. Taipei, Taiwan. April 06, 2021 – OBI Pharma, Inc. (TPEx: 4174) today announced the data highlighting the characteristics and antitumor efficacy of OBI-3424 and animal …